$-0.03 EPS Expected for PURE Bioscience (PURE)

October 13, 2017 - By Vivian Currie

 $ 0.03 EPS Expected for PURE Bioscience (PURE)

Investors wait PURE Bioscience (OTCMKTS:PURE) to report on October, 26. its quarterly earnings Wall Street analysts expect $-0.03 earnings per share, down $0.02 or 200.00 % from last year’s $-0.01 same quarter earnings. PURE Bioscience’s Wall Street analysts see 50.00 % negative EPS growth, taking into account the $-0.02 EPS reproted in the previous quarter, The stock increased 1.00% or $0.01 on October 12, reaching $1.03. About 8,832 shares traded. PURE Bioscience (OTCMKTS:PURE) has 0.00% since October 13, 2016 and is . It has underperformed by 16.70% the S&P500.

PURE Bioscience, Inc. is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The company has market cap of $64.83 million. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate . It currently has negative earnings. It offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains and food processors.

More important recent PURE Bioscience (OTCMKTS:PURE) news were published by: Forbes.com which released: “Pure Bioscience Looks For Silver Lining” on July 30, 2009, also Seekingalpha.com published article titled: “PURE Bioscience’s (PURE) CEO Hank Lambert on Q3 2017 Results – Earnings Call …”, Seekingalpha.com published: “PURE Bioscience’s (PURE) CEO Hank Lambert on Q2 2017 Results – Earnings Call …” on March 02, 2017. More interesting news about PURE Bioscience (OTCMKTS:PURE) was released by: Businesswire.com and their article: “PURE Bioscience Completes Successful Warrant Tender Offer and Raises $2.8 …” with publication date: October 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: